Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe-Reference-Cited by-同舟云学术

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe

Published:2018-07 Issue:1 Volume:74 Page:37-45
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

de Bono Johann S.^ORCID,Chowdhury Simon,Feyerabend Susan,Elliott Tony,Grande Enrique,Melhem-Bertrandt Amal^ORCID,Baron Benoit,Hirmand Mohammad,Werbrouck Patrick,Fizazi Karim

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr.

2. Mottet N, Bellmunt J, Briers E, et al. European Association of Urology. Guidelines on prostate cancer. http://uroweb.org/guideline/prostate-cancer/.

3. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study;Beer;J Clin Oncol,2014

4. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

5. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study;Shore;Lancet Oncol,2016

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2024-12

2. Efficacy and safety of interventions for metastatic castration resistant prostate cancer (mCRPC) patients progressing on androgen receptor-axis-targeted (ARAT) therapy: a systematic literature review;Current Medical Research and Opinion;2024-08-27

3. Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer;Clinical Cancer Research;2024-07-11

4. Impact of Novel Agents on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer;Anticancer Research;2024-06-26

5. The LAT1 inhibitor JPH203 suppresses the growth of castration‐resistant prostate cancer through a CD24‐mediated mechanism;Cancer Science;2024-04-24